Patients with Multiple Sclerosis:
An oral medication could be feasible for use in the near future.
Fingolimod, an oral medication, has shown good efficacy in a recent phase III trial when compared to interferon-beta-1a.
The annualized relapse rate at 12 months was 0.33 in the interferon-beta-1a group compared to 0.16 in the fingolimod group treated with 0.5mg daily.
An ongoing 2-year trial in which fingolimod is being compared to a placebo will provide a better idea about the long term efficacy and safety of this promising medication.